Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial

Publisher： Karger

E-ISSN： 1423-0194|102|1-2|18-25

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.102, Iss.1-2, 2015-03, pp. : 18-25

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment with the Radiolabelled Somatostatin Analog 177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 97, Iss. 4, 2013-05 ,pp. : 347-354

Karger

Access to resources Recommend Favorite

Functional Activity of the Multiligand Analog SOM230 at Human Recombinant Somatostatin Receptor Subtypes Supports Its Usefulness in Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 47-50

Karger

Access to resources Recommend Favorite

Quantitative Gene Expression of Somatostatin Receptors and Noradrenaline Transporter Underlying Scintigraphic Results in Patients with Neuroendocrine Tumors

By  

Neuroendocrinology, Vol. 87, Iss. 4, 2008-01 ,pp. : 223-232

Karger

Access to resources Recommend Favorite

Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact

By  

Hormone Research in Paediatrics, Vol. 84, Iss. 5, 2015-0 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro

By  

Hormone Research in Paediatrics, Vol. 76, Iss. 1, 2011-07 ,pp. : 111-112

Karger

Access to resources Recommend Favorite